EQT VIII Fund invests in Aldevron, supports capacity expansion

By Vassia Barba

- Last updated on GMT

(Imag: Getty/Jirapong Manustrong)
(Imag: Getty/Jirapong Manustrong)

Related tags Aldevron funding facility Investment

EQT VIII Fund set to acquire majority interest in plasmid DNA supplier Aldevron, announces investments to support the expansion of its production capacity.

The Fund aims to advance the R&D activity of Aldveron, as the North Dakota, US-based good manufacturing practice (GMP) supplier of DNA for commercial and clinical-stage gene therapies, continues to work to expand its capabilities.

The acquiring Fund announced its plans to support the company with investments in additional production capacity at its North Dakota campus as well, “furthering the Company's position as a key employer in North Dakota.”​ 

Aldevron recently announced plans to expand​ its headquarters’ campus in North Dakota by half a million-square-feet, which will lead to its annual capacity exceed $1bn worth of biologics production.

With this transaction, the EQT has now invested in US businesses within each of its three ‘core sectors’, healthcare, telecommunications, media & technology (TMT) and business services, stated Morten Hummelmose, Chairman of EQT.

The transaction is expected to close by the end of the year.

EQT has also previously invested in other companies in the US healthcare sector including Certara and Clinical Innovations and in healthcare companies of the Asian market, such as LaoBaiXing and MHC Asia.

Additionally, it has made investments in European healthcare companies including Biovian, Curaeos, Fertin Pharma, HyTest, Igenomix, Karo Pharma, Lima, Ottobock and WS Audiology.

Aldevron currently employs approximately 400 people in its facilities in North Dakota, Wisconsin, and Germany.

Related news

Show more

Related products

show more

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers